1-20 of 62
Barbara F. Eichhorst
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia Von Tresckow, Anna Maria Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah R. Kilfoyle, Gunnar Juliusson, Caspar Da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindström, Philipp Bernhard Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4639.
https://doi.org/10.1182/blood-2023-188827
Published: 2023
Journal Articles

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Rosemary Anne Harrup, Arnon P. Kater, Barbara F. Eichhorst, Carolyn Owen, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Yi Meng Chang, Rosemary Millen, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, John F. Seymour
Journal: Blood
Blood (2023) 142 (Supplement 1): 1898.
https://doi.org/10.1182/blood-2023-177567
Published: 2023
Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böttcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia Von Tresckow, Ursula Vehling-Kaiser, Clemens-Martin Wendtner, Kirsten Fischer, Karl Anton Kreuzer, Stephan Stilgenbauer, Philipp Bernhard Staber, Carsten Utoft Niemann, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 204.
https://doi.org/10.1182/blood-2023-188705
Published: 2023
Journal Articles

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 202.
https://doi.org/10.1182/blood-2023-174289
Published: 2023
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study

Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Vanitha Ramakrishnan, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1890.
https://doi.org/10.1182/blood-2023-173547
Published: 2023
Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Furstenau, Valentin Goede, Julia Von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens-Martin Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P. Kater, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2023) 142 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2023-178597
Published: 2023
Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3275.
https://doi.org/10.1182/blood-2023-174569
Published: 2023
Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Moritz Furstenau, Adam Giza, Anna-Maria Fink, Sandra Robrecht, Jonathan Weiss, Fanni Kleinert, Christof Schneider, Eugen Tausch, Kirsten Fischer, Petra Langerbeins, Othman Al-Sawaf, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 203.
https://doi.org/10.1182/blood-2023-173708
Published: 2023
Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1897.
https://doi.org/10.1182/blood-2023-173707
Published: 2023
Journal Articles

Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia

Billy Jebaraj, Rashmi Priyadharshini Dheenadayalan, Annika Müller, Jialei Qi, Eugen Tausch, Christof Schneider, Daniela Steinbrecher, Daniel Mertens, Felix Seyfried, Lüder Hinrich Meyer, André Lechel, Barbara F. Eichhorst, Courtney L Andersen, Giulia Fabbri, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 84.
https://doi.org/10.1182/blood-2023-188554
Published: 2023
Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Armin Riecke, Christof Schneider, Billy Jebaraj, Hassan Jumaa, Marc Young, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer, Eugen Tausch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1903.
https://doi.org/10.1182/blood-2023-179767
Published: 2023
Journal Articles

Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Doerfel, Joerg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Barbara F. Eichhorst, Michael Hallek, Kirsten Fischer, Anna Maria Fink
Journal: Blood
Blood (2023) 142 (Supplement 1): 4644.
https://doi.org/10.1182/blood-2023-185741
Published: 2023
Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 199.
https://doi.org/10.1182/blood-2023-180558
Published: 2023
Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Clinical Trials & Observations
John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D’Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (8): 839–850.
https://doi.org/10.1182/blood.2021015014
Published: 2022
Includes: Supplemental data
Journal Articles

Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies

Anthony R. Mato, MDMSCE, Kavita Sail, PhD, Maryam Sarraf Yazdy, MD, Brian T. Hill, MD, Mazyar Shadman, MD MPH, Beenish S Manzoor, PhD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Thomas Marshall, PharmD, MS, Jacqueline Nielsen, PhD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Anna Schuh, PhD, Toby A. Eyre, MD, William G. Wierda, MD PhD, Alan Skarbnik, MD, Lindsey E. Roeker, MD, Rajat Bannerji, MD PhD, James M. Pauff, MD PhD, Stephen J. Schuster, MD, George A Follows, MD PhD, Bruce D. Cheson, MD, Barbara F. Eichhorst, MD, Danielle M. Brander, MD, Irina Pivneva, PhD, Nicole Lamanna, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1756.
https://doi.org/10.1182/blood-2019-124600
Published: 2019
Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Kirsten Fischer, MD, Matthias Ritgen, Othman Al-Sawaf, MD, Sandra Robrecht, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Anke Schilhabel, PhD, Thomas Stübig, MD, Monika Brüggemann, MD, Yanwen Jiang, PhD, William Schary, PhD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Eugen Tausch, Karl-Anton Kreuzer, MD PhD, Anton W Langerak, PhD, Valentin Goede, MD, Sebastian Böttcher, MD, Stephan Stilgenbauer, MD, Michael Kneba, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 36.
https://doi.org/10.1182/blood-2019-125825
Published: 2019
Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Julia Von Tresckow, Paula Cramer, Nisha De Silva, MBBS, MRCP, FRCPath, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Petra Langerbeins, MD, Anna- Maria Fink, MD, Othman Al-Sawaf, MD, Moritz Fürstenau, MD, Thomas Illmer, MD, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3046.
https://doi.org/10.1182/blood-2019-125895
Published: 2019
Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3047.
https://doi.org/10.1182/blood-2019-131025
Published: 2019
Journal Articles

Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study

Mazyar Shadman, MD MPH, Kavita Sail, PhD, Beenish S Manzoor, PhD, Maryam Sarraf Yazdy, MD, Brian T. Hill, MD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Nnadozie Emechebe, MPH, Rajesh Kamalakar, MS, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Thomas Marshall, PharmD, MS, Jacqueline Nielsen, PhD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Anna Schuh, PhD, Toby A. Eyre, MD, Nicole Lamanna, MD, William G. Wierda, MD PhD, Alan Skarbnik, MD, Lindsey E. Roeker, MD, Rajat Bannerji, MD PhD, James M. Pauff, MD PhD, Stephen J. Schuster, MD, George A Follows, MD PhD, Bruce D. Cheson, MD, Barbara F. Eichhorst, MD, Danielle M. Brander, MD, Irina Pivneva, PhD, Annie Guerin, MSc, Anthony R. Mato, MDMSCE
Journal: Blood
Blood (2019) 134 (Supplement_1): 3048.
https://doi.org/10.1182/blood-2019-131401
Published: 2019